Bruce Han

Bruce Han

Company: New Bio Tx

Job title: Chief Executive Officer

Bio:

Dr. Han has over 20 years of drug discovery experience in the biopharmaceutical/ biotech industry in the US and China. Currently he is the CEO of NewBio Therapeutics. Inc. He received his BS degree in nuclear chemistry in 1982, MS degree in physical chemistry in 1985 both from Peking University, and Ph.D. in organic chemistry from Columbia University in 1990. He conducted postdoctoral research in antibody engineering in Professor Richard Lerner’s lab (1990-1994), and postdoctoral research in synthetic organic chemistry and medicinal chemistry in Professor Dale Boger’s Lab (1994-1996), both at The Scripps Research Institute. After working in Amgen (USA) for 12 years on small molecule drug discovery and 5 years in ShangPharma (Shanghai) as an executive director in medicinal chemistry, Dr. Han joined NewBio Therapeutics (NBT, Shanghai) in 2013 as CSO, and has led NBT’s antibody-drug conjugates (ADC) discovery efforts ever since. Dr. Han has led/worked with teams to put 5 small molecules and one ADC into clinical trials.

Seminars:

Improving Site-specific Conjugation Linkers & More Druggable ADCs 11:00 am

Gain an overview of NBT ADC pipeline Explore NBT’s site-specific conjugation technology Evaluate case studies of ADC discovery with site-specific conjugation technologyRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.